Premenstrual Syndrome - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 38 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Premenstrual Syndrome - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Premenstrual Syndrome - Pipeline Review, H1 2015', provides an overview of the Premenstrual Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premenstrual Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premenstrual Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Premenstrual Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Premenstrual Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Premenstrual Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Premenstrual Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Premenstrual Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Premenstrual Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Premenstrual Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Premenstrual Syndrome - Overview 7
Pipeline Products for Premenstrual Syndrome - Comparative Analysis 8
Premenstrual Syndrome - Therapeutics under Development by Companies 9
Premenstrual Syndrome - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Premenstrual Syndrome - Products under Development by Companies 13
Premenstrual Syndrome - Companies Involved in Therapeutics Development 14
DEKK-TEC, Inc. 14
M et P Pharma AG 15
Pherin Pharmaceuticals, Inc. 16
Umecrine Mood AB 17
Premenstrual Syndrome - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 26
PH-80PMD - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
progesterone - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
progesterone - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule-1 to Antagonize GABAA Receptor for PMDD - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule-2 to Antagonize GABAA Receptor for PMDD - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
UC-1010 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Premenstrual Syndrome - Recent Pipeline Updates 33
Premenstrual Syndrome - Dormant Projects 34
Premenstrual Syndrome - Product Development Milestones 35
Featured News & Press Releases 35
Sep 19, 2014: Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD) 35
Dec 16, 2013: Patient recruitment completed in the Phase I/II study of Umecrine Mood's candidate drug for severe premenstrual symptoms 36
May 23, 2013: Umecrine Mood Announces Dosing Of First Patient In Phase I/II Study Of UC1010 For Premenstrual Dysphoric Disorder 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables
Number of Products under Development for Premenstrual Syndrome, H1 2015 7
Number of Products under Development for Premenstrual Syndrome - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Premenstrual Syndrome - Pipeline by DEKK-TEC, Inc., H1 2015 14
Premenstrual Syndrome - Pipeline by M et P Pharma AG, H1 2015 15
Premenstrual Syndrome - Pipeline by Pherin Pharmaceuticals, Inc., H1 2015 16
Premenstrual Syndrome - Pipeline by Umecrine Mood AB, H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 25
Premenstrual Syndrome Therapeutics - Recent Pipeline Updates, H1 2015 33
Premenstrual Syndrome - Dormant Projects, H1 2015 34